Cardiothoracic & vascular anesthesia
Glucagon‐Like Peptide‐1 Agonist vs. Placebo and Pulmonary Decline After Open‐Heart Surgery: A Substudy of the GLORIOUS Randomised Clinical Trial
Authors' conclusion
While both diffusing capacity and ventilatory performance exhibited a mild-to-moderate decline 3 months after open-heart surgery, the GLP-1RA exenatide did not mitigate this decline compared with placebo.
Study context
- Population
- Adults undergoing non-emergent coronary artery bypass grafting (CABG) and/or surgical aortic valve replacement
- Participants
- 878 adults
- Comparison
- Exenatide vs placebo infusion during CPB and early postoperative period
- Primary endpoint
- Decline in DLCO and ventilatory performance (FEV1/FVC)
- Follow-up
- 3 months postoperative
Methodological detailspredefined explorative substudy
- Predefined explorative substudy
Primary result
As reported in the abstract
Decline in DLCO and FEV1/FVC, exenatide vs placebo
- No significant differences in decline between exenatide and placebo
- all p > 0.3
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| DLCO (% predicted corrected), all patients, preoperative vs 3 months · 3 months postoperativeMedian 80% preoperative to 72% postoperative | difference −7.7 percentage point (95% CI 6.2–9.1) | P < 0.001 |
| FEV1/FVC, all patients, preoperative vs 3 months · 3 months postoperative0.75 preoperative to 0.73 postoperative | difference −1.6 (95% CI 1.0–2.1) | P < 0.001 |
Subgroup analyses (subgroup)
- Findings consistent across subgroup analyses
Original publication
Glucagon‐Like Peptide‐1 Agonist vs. Placebo and Pulmonary Decline After Open‐Heart Surgery: A Substudy of the GLORIOUS Randomised Clinical Trial. Acta Anaesthesiol Scand. Published 19 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →